Metabolic and molecular effects of high-fat diet (HFD). by Ping-yu Cai (12389929)

Mean velocity and ball angle profiles across first and last 10 trials of block 2 for every subject. by Salah Bazzi (11851767)

Svaldi et al.’s “High Load” and “Low Load” groups from a soccer season (High Load percentiles: 25th = 4515 g, 50th = 5615 g, 75th = 12313 g; Low Load percentiles: 25th = 2425 g, 50... by Joshua Auger (9530081)

“…<p>Post-season adjustments to the High Load group: 19.7% reduction from decreasing inflation pressure from 1.10 bar (16 psi) to 0.55 bar (8 psi), 7.1% reduction from downsizing a size 5, 0.55 bar (8 psi) ball to size 4.5, 0.55 bar (8 psi) ball (<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0240162#pone.0240162.t003" target="_blank">Table 3</a>), and a 20% reduction in number of hits based on average PLA per hit (Adjusted High Load percentiles: 25th = 2463 g, 50th = 3063 g, 75th = 6718 g).…”

Expression of mAChR M1, M2, M3, M4, and M5 mRNA in the mid colon. by Ji Eun Kim (403026)

Hematopoietic and neuronal SDS phenotypes are p53-dependent. by Marina E. Tourlakis (751986)

miR-150-5p inhibition modulates pyroptosis and FoxO3a/ARC signaling in ApoE^-/- mice. by Ping-yu Cai (12389929)

Therapeutic effects of miR-150-5p inhibition on ox-LDL-induced pyroptosis in RAW264.7 macrophages. by Ping-yu Cai (12389929)

Image2_First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis.TIF by Qiao Liu (346535)

“…</p><p>Conclusion: For advanced NSCLC patients with PD-L1 of at least 50%, cemiplimab was a cost-effective option compared with pembrolizumab and a dominant alternative against atezolizumab. …”

Image1_First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis.TIFF by Qiao Liu (346535)

“…</p><p>Conclusion: For advanced NSCLC patients with PD-L1 of at least 50%, cemiplimab was a cost-effective option compared with pembrolizumab and a dominant alternative against atezolizumab. …”

Image3_First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis.TIF by Qiao Liu (346535)

“…</p><p>Conclusion: For advanced NSCLC patients with PD-L1 of at least 50%, cemiplimab was a cost-effective option compared with pembrolizumab and a dominant alternative against atezolizumab. …”

Decrease in the absorbance of PEG₄₀-CONH-(CH₂)₅-CONH-(CH₂)₆-NHCO-MTX with time during dialysis against 1mM HCl. by Itzik Cooper (2873291)

Optogenetic stimulation of CA1 astrocytes for 5- or 10-min had no significant effect on cognitive function. by Jae-Hong Kim (124622)

Decrease of MMP-2 and VEGF expression caused by RNA interference of APN/CD13 in ES-2 cells using MMP-2 and VEGF ELISA kit by Mikio Terauchi (35139)

Dysregulation of miR-150-5p and its target FoxO3a in atherosclerosis (AS). by Ping-yu Cai (12389929)

Mutation of vOPG147 F55, T116 and T117 does not affect replication and production of VACV. by Xue-Mei Yi (18851202)

Inhibiting translation in 5-HT neurons does not recapitulate a <i>Minute</i> phenotype. by Lisa Patricia Deliu (13570709)

Potent Sensitisation of Cancer Cells to Anticancer Drugs by a Quadruple Mutant of the Human Deoxycytidine Kinase by Safiatou T. Coulibaly (816058)

“…Importantly, a remarkable effect is also observed in treatments with the anticancer compound cytarabine (AraC), for which a 10,000 fold decrease in IC50 occurred. …”

The sequence of the trial. by Junhui Kim (18575083)

Subjects:

Estimated covariance parameter and fixed coefficients for the authorship questionnaire, comparing the “self” to the “delay” response. by Junhui Kim (18575083)

Subjects:

Fig 8 - by Junhui Kim (18575083)

Subjects: